The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00964236|
Recruitment Status : Completed
First Posted : August 24, 2009
Last Update Posted : January 4, 2018
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2011|
Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Other Name: Kuvan
Healthy individuals without phenylketonuria (PKU).
- functional magnetic resonance imaging of the brain [ Time Frame: baseline, 4 week, & 6 month follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00964236
|United States, Missouri|
|University of Missouri|
|Columbia, Missouri, United States, 65211|
|Principal Investigator:||Shawn E Christ, Ph.D.||University of Missouri-Columbia|